Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zhendong Chen"'
Autor:
Xiaoyan Chen, Guangze Li, Xingxing Diao, Zitao Guo, Mengling Liu, Jinghua Yu, Qi Huang, Jian Meng, Yaru Xue, Dafang Zhong, Yuandong Zheng, Zhendong Chen, Yali Wu
Publikováno v:
Drug Metabolism and Disposition. 50:809-818
Excretion of [14C]HR011303-derived radioactivity showed significant species difference. Urine (81.50% of dose) was the main excretion route in healthy male subjects, whereas feces (87.16% of dose) was the main excretion route in rats. To further eluc
Autor:
Jian-jun Zou, Yifan Zhang, Dafang Zhong, Xiao-fei Chen, Xin liang, Y. L. Zhu, Yan-mei Liu, Qian Chen, Hai-yan Liu, Jingying Jia, Zhendong Chen, Chen Yu, Yan Zhan
Publikováno v:
Clinical Therapeutics. 43:e264-e273
Purpose Henagliflozin is a highly selective and effective sodium glucose co-transporter (SGLT)-2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of meal intake on the
Autor:
Hua Zhang, Yifan Zhang, Xiao-yun Liu, Jing-Jing Bao, Liyan Miao, Zhendong Chen, Yong Jiang, Dafang Zhong, Jian Meng
Publikováno v:
Acta Pharmacol Sin
Furmonertinib was designed for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. In this study, we investigated the metabolic disposition and mass balance in humans and tissue distribution in rats. After a single
Autor:
Zhenggang Ren, Xiao Zhang, Ying Liu, Linna Wang, Jianping Xiong, Hui Li, Jianjun Zou, Xiaojing Zhang, Shukui Qin, Zhendong Chen, Zhiqiang Meng
Publikováno v:
Drug Design, Development and Therapy
Hui Li,1,* Shukui Qin,1,* Ying Liu,2 Zhendong Chen,3 Zhenggang Ren,4 Jianping Xiong,5 Zhiqiang Meng,6 Xiao Zhang,7 Linna Wang,7 Xiaojing Zhang,7 Jianjun Zou7 1Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundEmerging clinical data suggest that an immune checkpoint inhibitor in combination with an antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the combination of camrelizumab with apatinib in pretreated advan